Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

After Recognify Life Sciences Inc.’s phase IIb failure in treating the cognitive impairment in those with schizophrenia, the indication is no closer to a U.S. FDA approved therapy. The ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized ...

INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a ...

Individuals with word-finding difficulties during prodromal migraine showed reduced objective performance in metrics of language, memory and processing speed compared with those who did have such ...

The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ( ...

In modern society, sleep is often sacrificed at the altar of productivity. With the demands of work, social obligations, and digital distractions, it ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...